Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitroglycerin topical - Covis Pharma/MediQuest

Drug Profile

Nitroglycerin topical - Covis Pharma/MediQuest

Alternative Names: MQX-503; Vascana

Latest Information Update: 26 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediQuest Therapeutics
  • Developer Covis Pharma; MediQuest Therapeutics
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Raynaud's disease

Most Recent Events

  • 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in Canada (Topical,gel)
  • 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in European Union (Topical,gel)
  • 26 Sep 2017 No recent reports on development identified - Phase-III for Raynaud's disease in USA (Topical,cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top